Bristol Myers Squibb Launches Campaign to Address Gaps in Cardiovascular Care

Event summary

  • Bristol Myers Squibb (BMY) launched the 'Change the Target. Change What’s Possible.' campaign with Johnson & Johnson to highlight unmet needs in cardiovascular and thromboembolic care.
  • The campaign underscores that 40% of atrial fibrillation patients are untreated or undertreated, and 25% of strokes are recurrent and preventable.
  • Factor XIa inhibition is identified as a potential solution to reduce thrombosis without increasing bleeding risk.
  • The collaboration aims to leverage combined scientific expertise to improve patient outcomes in thromboembolic disease management.

The big picture

The campaign highlights the persistent challenges in cardiovascular care, where current therapies often require trade-offs between efficacy and bleeding risks. The collaboration between Bristol Myers Squibb and Johnson & Johnson represents a strategic effort to address these gaps through innovative research and targeted therapies. This initiative is part of a broader industry trend toward precision medicine and the development of safer, more effective treatments for thromboembolic diseases.

What we're watching

Therapeutic Innovation
How the focus on factor XIa inhibition will impact the development of next-generation anticoagulants.
Market Dynamics
Whether the Bristol Myers Squibb-Johnson & Johnson collaboration can effectively close gaps in thromboembolic disease management.
Regulatory Landscape
The pace at which new therapies targeting factor XIa will gain regulatory approval and market adoption.

Related topics

Pharmaceuticals